ERIKA LEAKEY: Open Payments
NPI 1710962873 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,005 in 44 payments from 13 companies in 2025. Trend: 2023 $989 · 2024 $1,389 · 2025 $1,005
Food & beverage: $1,005
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 6 | $171 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $163 |
| Janssen Biotech, Inc. | 5 | $109 |
| ABBVIE INC. | 5 | $106 |
| Celltrion USA Inc. | 4 | $86 |
| Aimmune Therapeutics, Inc. | 4 | $78 |
| Lilly USA, LLC | 2 | $58 |
| QOL Medical, LLC | 2 | $54 |
| Madrigal Pharmaceuticals | 2 | $51 |
| Ardelyx, Inc. | 2 | $45 |
Products named: DUPIXENT, ENTYVIO, TREMFYA, RINVOQ, VEGZELMA, ZENPEP, OMVOH, Sucraid.
Industry payments across TX — which companies pay providers there.
